Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Ibandronate, commonly known as Ibandronic Acid, is a potent nitrogen-containing bisphosphonate widely utilized in the management of bone-related disorders. Its chemical identity is defined by the molecular formula C6H12NO7P2 and carries the CAS Registry Number 10488-58-3. Structurally, it features two phosphonate groups attached to a carbon backbone, which allows for high affinity binding to hydroxyapatite crystals within the bone matrix. This unique structural characteristic is the foundation of its therapeutic mechanism, enabling it to selectively target areas of high bone turnover.
The primary clinical application of Ibandronate is the treatment and prevention of osteoporosis in postmenopausal women. By inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS) within the mevalonate pathway, it effectively suppresses the activity and induces apoptosis of osteoclasts, the cells responsible for bone resorption. Consequently, this action slows down bone loss, increases bone mineral density, and significantly reduces the risk of vertebral fractures. Unlike some other bisphosphonates, Ibandronate has demonstrated efficacy specifically against vertebral compression fractures, though its impact on non-vertebral fractures remains less pronounced compared to agents like alendronate or zoledronic acid.
Administration is typically oral, often available as monthly tablets, or intravenous infusion administered quarterly. The oral bioavailability is low, necessitating strict administration protocols involving fasting and remaining upright for at least one hour to minimize gastrointestinal irritation. While generally well-tolerated, potential side effects may include esophageal discomfort, musculoskeletal pain, and rarely, osteonecrosis of the jaw or atypical femoral fractures with long-term use. Due to its pharmacokinetic profile and targeted efficacy, Ibandronate remains a valuable option in the armamentarium against metabolic bone diseases, offering flexibility in dosing schedules to improve patient compliance while maintaining robust skeletal protection.